Cargando…

miRNA Levels as a Biomarker for Anti-VEGF Response in Patients with Diabetic Macular Edema

Background: The aim of this study was to investigate whether miRNA levels in the circulation could serve as a predictive biomarker for responsiveness to anti-vascular endothelial growth factor (VEGF) therapy in patients with diabetic macular edema. Methods: Whole blood samples were collected at base...

Descripción completa

Detalles Bibliográficos
Autores principales: Vader, Maartje J. C., Habani, Yasmin I., Schlingemann, Reinier O., Klaassen, Ingeborg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708164/
https://www.ncbi.nlm.nih.gov/pubmed/34945769
http://dx.doi.org/10.3390/jpm11121297
_version_ 1784622615302766592
author Vader, Maartje J. C.
Habani, Yasmin I.
Schlingemann, Reinier O.
Klaassen, Ingeborg
author_facet Vader, Maartje J. C.
Habani, Yasmin I.
Schlingemann, Reinier O.
Klaassen, Ingeborg
author_sort Vader, Maartje J. C.
collection PubMed
description Background: The aim of this study was to investigate whether miRNA levels in the circulation could serve as a predictive biomarker for responsiveness to anti-vascular endothelial growth factor (VEGF) therapy in patients with diabetic macular edema. Methods: Whole blood samples were collected at baseline from 135 patients who were included in the BRDME study, a randomized controlled comparative trial of monthly bevacizumab or ranibizumab treatment for 6 months in patients with diabetic macular edema (Trialregister.nl, NTR3247). Best corrected visual acuity letter score (BCVA) and retinal central area thickness (CAT) were measured monthly during the 6-month follow-up. Levels of selected miRNAs were quantified. Results: Following linear regression analysis, the levels of four miRNAs were negatively associated with baseline CAT. Multivariable regression analysis confirmed this association for miR-181a. No associations with changes in CAT after 3 or 6 months of anti-VEGF treatment were found. In addition, no associations with miRNA levels with baseline BCVA or change in BCVA after 3 or 6 months of anti-VEGF treatment were found. Conclusions: Circulating miR-181a levels were negatively associated with CAT at baseline. However, no associations between miRNA levels and the response to anti-VEGF therapy were found.
format Online
Article
Text
id pubmed-8708164
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87081642021-12-25 miRNA Levels as a Biomarker for Anti-VEGF Response in Patients with Diabetic Macular Edema Vader, Maartje J. C. Habani, Yasmin I. Schlingemann, Reinier O. Klaassen, Ingeborg J Pers Med Article Background: The aim of this study was to investigate whether miRNA levels in the circulation could serve as a predictive biomarker for responsiveness to anti-vascular endothelial growth factor (VEGF) therapy in patients with diabetic macular edema. Methods: Whole blood samples were collected at baseline from 135 patients who were included in the BRDME study, a randomized controlled comparative trial of monthly bevacizumab or ranibizumab treatment for 6 months in patients with diabetic macular edema (Trialregister.nl, NTR3247). Best corrected visual acuity letter score (BCVA) and retinal central area thickness (CAT) were measured monthly during the 6-month follow-up. Levels of selected miRNAs were quantified. Results: Following linear regression analysis, the levels of four miRNAs were negatively associated with baseline CAT. Multivariable regression analysis confirmed this association for miR-181a. No associations with changes in CAT after 3 or 6 months of anti-VEGF treatment were found. In addition, no associations with miRNA levels with baseline BCVA or change in BCVA after 3 or 6 months of anti-VEGF treatment were found. Conclusions: Circulating miR-181a levels were negatively associated with CAT at baseline. However, no associations between miRNA levels and the response to anti-VEGF therapy were found. MDPI 2021-12-04 /pmc/articles/PMC8708164/ /pubmed/34945769 http://dx.doi.org/10.3390/jpm11121297 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vader, Maartje J. C.
Habani, Yasmin I.
Schlingemann, Reinier O.
Klaassen, Ingeborg
miRNA Levels as a Biomarker for Anti-VEGF Response in Patients with Diabetic Macular Edema
title miRNA Levels as a Biomarker for Anti-VEGF Response in Patients with Diabetic Macular Edema
title_full miRNA Levels as a Biomarker for Anti-VEGF Response in Patients with Diabetic Macular Edema
title_fullStr miRNA Levels as a Biomarker for Anti-VEGF Response in Patients with Diabetic Macular Edema
title_full_unstemmed miRNA Levels as a Biomarker for Anti-VEGF Response in Patients with Diabetic Macular Edema
title_short miRNA Levels as a Biomarker for Anti-VEGF Response in Patients with Diabetic Macular Edema
title_sort mirna levels as a biomarker for anti-vegf response in patients with diabetic macular edema
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708164/
https://www.ncbi.nlm.nih.gov/pubmed/34945769
http://dx.doi.org/10.3390/jpm11121297
work_keys_str_mv AT vadermaartjejc mirnalevelsasabiomarkerforantivegfresponseinpatientswithdiabeticmacularedema
AT habaniyasmini mirnalevelsasabiomarkerforantivegfresponseinpatientswithdiabeticmacularedema
AT schlingemannreiniero mirnalevelsasabiomarkerforantivegfresponseinpatientswithdiabeticmacularedema
AT klaasseningeborg mirnalevelsasabiomarkerforantivegfresponseinpatientswithdiabeticmacularedema